Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2024-09-09 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
2024年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2024 second extraordinary general meeting of shareholders of Harbin Yuheng Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, only the official voting results and meeting details. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2024-09-09 Chinese
2024年第二次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and procedural compliance of a company's 2024 second extraordinary shareholders' meeting. It details the convening, attendance, voting procedures, and results of the meeting. It does not contain financial statements or management discussion but focuses on the legal validation of the shareholders' meeting and its resolutions. This type of document is typically classified as a Regulatory Filing (RNS) because it is a legal opinion related to corporate governance and shareholder meeting compliance, not a direct report like an Annual Report or Proxy Statement. The document length is 2832 characters, which is relatively short and consistent with a legal opinion letter rather than a full report.
2024-09-09 Chinese
2024年限制性股票激励计划预留授予激励对象名单
Capital/Financing Update Classification · 95% confidence The document is a list of reserved grant recipients under a 2024 restricted stock incentive plan for Harbin Yuheng Pharmaceutical Co., Ltd. It details the allocation of restricted stock to core management and technical personnel, including names and positions. There is no financial data, no mention of financial results, no regulatory certifications, or voting results. The document is an announcement related to stock incentive plans, which is a capital-related update but not a full financing or capital structure change report. It is not a report publication announcement since it contains substantive content about the incentive plan allocation. The best fitting category is Capital/Financing Update (CAP) because it updates on company stock incentive allocations, which affect capital structure and financing incentives.
2024-09-03 Chinese
关于向激励对象授予预留限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the granting of reserved restricted stocks to incentive recipients under the 2024 restricted stock incentive plan. It includes specifics such as the grant date, number of shares, price, approval procedures, performance assessment requirements, impact on financials, and legal opinions. The content focuses on the company's stock incentive plan and related corporate governance matters rather than financial results, earnings, or regulatory filings. It is not a full annual or interim report, nor an earnings release or call transcript. It is also not a simple announcement of a report publication but a substantive disclosure about a capital incentive plan. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to changes in capital structure and equity incentives.
2024-09-03 Chinese
2024年限制性股票激励计划预留授予事项的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2024 restricted stock incentive plan reserved grant matters of Harbin Yuheng Pharmaceutical Co., Ltd. It details the legal review and compliance of the stock incentive plan, including approvals, grant date, grant objects, quantities, prices, and conditions. The document is a standalone legal opinion related to a specific corporate action (stock incentive plan) and does not contain financial statements or earnings data. It is not an annual report, earnings release, or management discussion. It is also not a regulatory announcement or a report publication announcement. The document fits best under the category of Audit Report / Information (AR) as it is a legal opinion verifying compliance and legality of a corporate action, which is typical for audit or legal opinion reports related to corporate governance and compliance matters. FY 2024
2024-09-03 Chinese
第六届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the sixteenth meeting of the sixth board of directors of Harbin Yuheng Pharmaceutical Co., Ltd. It details the approval of a restricted stock incentive plan and the granting of reserved restricted shares to incentive recipients. The document includes meeting attendance, voting results, and references to related announcements published elsewhere. It does not contain full financial statements or detailed financial performance data, nor is it a transcript or presentation. It is an announcement of board decisions related to management incentives, which fits the category of Board/Management Information (MANG). The document length is short and focused on board resolutions, not a full report or regulatory filing. Therefore, the classification is MANG with high confidence.
2024-09-03 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.